Location of Primary Tumor Matters in Colorectal Cancer

Video

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

The results of the study (abstract 3504) were presented at the 2016 American Society of Clinical Oncology Anual Meeting and showed that patients with left-side tumors-those originating in the descending colon, the sigmoid colon, or the rectum-survived significantly longer than those with tumors originating on the right side, in the ascending colon or the cecum (median overall survival of 33.3 months vs 19.4 months).

In this video, Alan P. Venook, MD, of the Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses the results.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content